Adverse pregnancy outcomes

1 paper4 findings

Human observational research associates adverse pregnancy outcomes with cardiovascular-kidney-metabolic syndrome. In women followed for 11.68 years, it reports higher overall syndrome and stage 4 risk, but no effect on stage 3. All four findings come from one lab in one country, without independent replication.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Heart, Lung, and Blood Institute and 2 more

Humans1

Outcomes

Cardiovascular-kidney-metabolic syndrome stage 3

no changein humans1

1 study

Adverse pregnancy outcomes have no effect on cardiovascular-kidney-metabolic syndrome stage 3 in humans.
Humans11.68 yearsfemalesn = 2,575
Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study
Frontiers in cardiovascular medicine21 Aug 2026

More on Cardiovascular-kidney-metabolic syndrome stage 3

Associations

Cardiovascular-kidney-metabolic syndrome

upin humans1HR 1.27

1 study

Adverse pregnancy outcomes raise the risk of cardiovascular-kidney-metabolic syndrome in humans (HR 1.27, 95% CI 1.01-1.61).
Humans11.68 yearsfemalesn = 2,575
Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study
Frontiers in cardiovascular medicine21 Aug 2026
Adverse pregnancy outcomes are associated with cardiovascular-kidney-metabolic syndrome in humans (OR 2.93, 95% CI 1.74-4.94).
Humansfemalesn = 2,738
Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study
Frontiers in cardiovascular medicine21 Aug 2026

More on Cardiovascular-kidney-metabolic syndrome

Cardiovascular-kidney-metabolic syndrome stage 4

upin humans1

1 study

Adverse pregnancy outcomes raise the risk of cardiovascular-kidney-metabolic syndrome stage 4 in humans.
Humans11.68 yearsfemalesn = 2,575
Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study
Frontiers in cardiovascular medicine21 Aug 2026

More on Cardiovascular-kidney-metabolic syndrome stage 4

Funding

4 grants since 2023

National Heart, Lung, and Blood InstituteUS$1.2mNational Institute on AgingUS$1.9mNational Institute of Neurological Disorders and StrokeUS$554.5k

Latest

1 in 12 months

Frontiers in Cardiovascular Medicine6 Sep

Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study

Cohort study of 2,738 peopleCardiovascular-kidney-metabolic syndrome

Paper

Adverse pregnancy outcomes

Outcomes

Associations

Funding

Latest

Association between adverse pregnancy outcomes and incidence of advanced cardiovascular-kidney-metabolic disease: a population-based cohort study

Related